17 results about "Primary sclerosing cholangitis" patented technology

The invention relates to the field of biomedicine, particularly provides a copper-based nano-enzyme as well as a preparation method and application thereof, and aims to solve the problems that in the prior art, clinical treatment on primary sclerosing cholangitis (PSC) is difficult in diagnosis and lacks of effective treatment drugs. The copper-based nano-enzyme comprises a nano-enzyme carrier and a copper-based nano-enzyme, wherein the nano-enzyme carrier is a two-dimensional nanosheet formed by copper ions, gallic acid and ursodesoxycholic acid through coordinate bonds; the probe molecule is a cyanine dye molecule connected to the surface of the nano-enzyme carrier through a covalent bond; wherein the fluorescence intensity of the copper-based nano enzyme is enhanced after the action of the alkaline phosphatase. The three functions of alkaline phosphatase responsive diagnosis, nano-enzyme catalytic treatment and ursodesoxycholic acid hepatic targeting are innovatively and synergistically integrated into one nano platform, the treatment function can be executed while specific imaging diagnosis is performed on diseases, and a new strategy is provided for diagnosis and treatment of diseases such as PSC.

This invention relates to the use of a recombinant protein ANG in the preparation of medicaments for treating cholestatic liver disease. Specifically, this invention provides the use of the angiopoietin ANG gene, or its protein, or its promoter, for the preparation of medicaments, compositions, or formulations for the prevention, improvement, and / or treatment of cholestatic liver disease. It is particularly effective in treating primary biliary cholangitis and primary sclerosing cholangitis.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives of Formula (I): or a salt or prodrug thereof. These compounds are TLR9 inhibitors useful for the treatment, prevention or slowing of a fibrotic disease, such as liver fibrosis, kidney fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic nephropathy, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The present application relates to the biomedical field, and specifically provides a copper-based nano-enzyme, a preparation method and application thereof, aiming to solve the problems of diagnosis difficulty and lack of effective treatment drugs in the prior art for the treatment of primary sclerosing cholangitis (PSC) in clinical practice. To this end, the copper-based nano-enzyme comprises: a nano-enzyme carrier, which is a two-dimensional nanosheet formed by coordination bonds between copper ions, gallic acid and ursodeoxycholic acid; and a probe molecule, which is a phycobilin dye molecule connected to the surface of the nano-enzyme carrier by a covalent bond; wherein the copper-based nano-enzyme has enhanced fluorescence intensity after the action of alkaline phosphatase. The present application innovatively integrates alkaline phosphatase-responsive diagnosis, nano-enzyme catalytic treatment and liver targeting of ursodeoxycholic acid into one nano-platform, can perform treatment functions while performing specific imaging diagnosis on diseases, and provides a new strategy for the diagnosis and treatment of PSC and other diseases.

The present invention relates to elafibranor or its active metabolite, for use in a method for the treatment of primary sclerosing cholangitis.

The invention relates to the technical field of medicines, and finds that a natural product amentoflavone can be used as a GPR35 (G-protein coupled receptor 35, GPR35) receptor agonist and application thereof, the compound is amentoflavone, has GPR35 receptor agonist activity, is a GPR35 receptor agonist, can be used for treating thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction, and can be used for treating various diseases such as thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction. Therefore, a novel GPR35 receptor stimulant seedling compound with a clear action target can be provided for the related diseases.

The invention discloses application of a mononuclear macrophage PKM2 in preparation of a product for treating and / or preventing primary sclerosing cholangitis (PSC), and belongs to the technical field of biological medicine. The expression or activity of the mononuclear macrophage PKM2 is regulated in a targeted mode from multiple angles, reactive bile duct hyperplasia can be remarkably reduced in the PSC treatment process, liver injury can be relieved, fibration around the bile duct can be inhibited, and the purpose of specifically and effectively inhibiting PSC development can be achieved. Therefore, the targeted mononuclear macrophage PKM2 provided by the invention can be used as a new strategy for PSC treatment, and is used for targeted treatment of PSC.

To provide a suitable means for delivering a therapeutic biomolecule to a patient, wherein a stable and therapeutically effective blood level of the biomolecule occurs in a stable and convenient form over an extended period of time.SOLUTION: Provided is a device for treating a disease in a subject, wherein the subject may have Crohn's disease, ulcerative colitis, primary sclerosing cholangitis, eosinophilic esophagitis, autoimmune hepatitis, the device comprising a cell chamber comprising a population of cells that secrete a biomolecule for delivery to the subject.SELECTED DRAWING: None

The present invention relates to a pharmaceutical composition for preventing or treating cholestatic liver disease, comprising beta-lapachone and ursodeoxycholic acid as active ingredients. Specifically, by orally administering beta-lapachone and ursodeoxycholic acid in combination, the composition is expected to contribute to the treatment of patients with primary sclerosing cholangitis or inflammatory bowel disease accompanied by primary sclerosing cholangitis, which are difficult to treat, by reducing the concentration of TNF-alpha in the blood of the patients and by also significantly reducing the severity of primary sclerosing cholangitis.

The application discloses a RICTOR protein molecule inhibitor, which is an mTORC2 inhibitor siRictor, a specific inhibitor of an mTORC2 functional subunit RICTOR, and realizes reduction of RICTOR expression. The mTORC2 activity inhibitor can be applied to preparation of a medicine for inhibiting cell proliferation, in particular, cholangiocarcinoma cell proliferation, including various dosage forms such as oral preparations and injections, and can be used alone or in combination with other anti-tumor medicines and scientific research reagents, and is used for treating and preventing cholangiocarcinoma, primary sclerosing cholangitis and other liver and bile duct diseases caused by abnormal proliferation of cholangiocytes, and in vitro cholangiocyte proliferation related research.

This disclosure relates to compounds of formula (I-1) or (I-2): This relates to TIFF2026513962000575.tif74102. The compounds of this disclosure can inhibit the activity of tyrosine kinase 2 (TYK2), for example, in inflammation, autoimmune diseases, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoidosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischemia, reperfusion injury, cerebral edema, head trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retina It is useful in treating diseases or disorders such as inflammation, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infections, myalgia, endotoxin shock, toxic shock syndrome, autoimmune diseases, osteoporosis, multiple sclerosis, endometriosis, menstrual pain, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis, and sunburn. This disclosure further provides a method for preparing the compound.

This document relates to flavonoid compounds and methods and materials for using flavonoid compounds to treat one or more fibrotic and / or aberrant wound healing / scarring conditions (e.g., idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)). For example, one or more flavonoid compounds having the structure of Formula (I) can be administered to a mammal (e.g., a human) having one or more fibrotic and / or aberrant wound healing / scarring conditions (e.g., IPF, NASH, and PSC) to treat the mammal.

The present disclosure relates to a method of a method of treating a cholangiopathy (e.g., Primary Sclerosing Cholangitis or Primary Biliary Cholangitis) in a human subject in need thereof, comprising administering a therapeutically effective amount of an anti-Claudin-1 antibody to the human subject.

The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I): or a salt thereof. These compounds are TLR9 compounds suitable for use in the treatment, prevention or slowing of a fibrotic disease, such as liver fibrosis, kidney fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic nephropathy, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The present invention provides a compound of formula (I), a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof for use in preventing, inhibiting, or treating a condition or disorder mediated by urocanic acid reductase, wherein A is a 5-membered heteroaromatic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, at least one of the heteroatoms being nitrogen, R 1 and R 2 are independently selected from -H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy, halogen, and -CN, and when present, each R 3 is C 1-6 alkyl, C 1-6 alkoxy, C 1-3 alkoxy, halogen, -OH, -CN, -NO2, -NR 5 R 6 (wherein R 5 and R 6 are independently selected from H and C 1-3 alkyl), and -C(=NR 7 )(NR 8 R 9 (wherein each of R 7 , R 8 , and R 9 is independently selected from H and C 1-3 alkyl), and R 4 is selected from -OH, -SH, C 1-6 alkoxy, and -NR 10 R 11 (wherein R 10 and R 11 are independently selected from H and C 1-3 alkyl), and n is an integer from 0 to 2. Such compounds are particularly suitable for use in preventing, inhibiting, or treating gastrointestinal disorders or conditions, cardiovascular diseases or disorders, and metabolic disorders, such as, but not limited to, primary sclerosing cholangitis (PSC), cardiomyopathy, heart failure, type 2 diabetes, and prediabetes. The present invention further provides certain novel compounds, methods for their preparation, and pharmaceutical compositions containing such compounds. JPEG2026525257000099.jpg25128